MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
Meral SeferoĞluÖzlem EthemoğluÖmer Faruk TuranAksel SivaPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)
These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.